Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half‐life

There is keen interest in elucidating the biological mechanisms underlying recent failures of β‐site amyloid precursor protein–cleaving enzyme‐1 (BACE1) inhibitors in Alzheimer's disease trials.

• Publication year

  2019

• Venue

  Alzheimer's & Dementia

• Publication date

  2019-08-12

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jalz.2019.06.3918PMID 31416794PMCID PMC6756967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Repurposed agents in the Alzheimer’s disease drug development pipeline

  2020cited by this paper
• Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.

  2019cited by this paper
• A cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor

  2019cited by this paper
• Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease

  2019cited by this paper
• Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.

  2018cited by this paper
• Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease

  2018cited by this paper
• BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology

  2018cited by this paper
• Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice

  2018cited by this paper
• Alzheimer's disease drug development pipeline: 2017

  2017cited by this paper
• BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

  2017cited by this paper
• Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606

  2017influential reference
• Cell-type Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability

  2017cited by this paper
• Semagacestat Is a Pseudo-Inhibitor of γ-Secretase.

  2017cited by this paper
• Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy.

  2017cited by this paper
• AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

  2016cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.

  2016cited by this paper
• The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease

  2016cited by this paper
• Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability.

  2015cited by this paper
• Targeting the β secretase BACE1 for Alzheimer's disease therapy.

  2014cited by this paper
• A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

  2013cited by this paper
• Dual Cleavage of Neuregulin 1 Type III by BACE1 and ADAM17 Liberates Its EGF-Like Domain and Allows Paracrine Signaling

  2013cited by this paper
• β-Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects*♦

  2012cited by this paper
• Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

  2012cited by this paper
• BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization

  2010cited by this paper
• Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics

  2009cited by this paper
• BACE1 regulates voltage-gated sodium channels and neuronal activity

  2007cited by this paper
• BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.

  2004cited by this paper
• Gene structure and organization of the human beta-secretase (BACE) promoter.

  2004cited by this paper
• Gene structure and organization of the human β‐secretase (BACE) promoter

  2004cited by this paper
• The Cell Adhesion Protein P-selectin Glycoprotein Ligand-1 Is a Substrate for the Aspartyl Protease BACE1*

  2003cited by this paper
• Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme.

  2001cited by this paper
• Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.

  2000cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

  1999cited by this paper
• Purification and cloning of amyloid precursor protein β-secretase from human brain

  1999cited by this paper

• Roburic acid inhibits glucocorticoid-induced osteonecrosis of the femoral head associated osteoclast activity via targeting PTP1B.

  2026cites this paper
• Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein

  2025cites this paper
• Proposed Therapeutic Strategy to Combat Alzheimer's Disease by Targeting Beta and Gamma Secretases.

  2025cites this paper
• Disruption of BAG3-mediated BACE1 stabilization alleviates neuropathology and memory deficits in a mouse model of Alzheimer’s disease

  2025cites this paper
• Roburic acid inhibits lung cancer metastasis and triggers autophagy as verified by network pharmacology, molecular docking techniques and experiments

  2024cites this paper
• Gentidelasides A-G: loganin derivatives from Gentiana delavayi with reducing Aβ secretion via suppressing BACE1 expression.

  2024cites this paper
• Computational identification of promising therapeutics via BACE1 Targeting: Implications for Alzheimer's disease.

  2024cites this paper
• Discovery of a CK2α'-Biased ATP-Competitive Inhibitor from a High-Throughput Screen of an Allosteric-Inhibitor-Like Compound Library.

  2024cites this paper
• Substances of Natural Origin in Medicine: Plants vs. Cancer

  2023cites this paper
• Neuroprotective effect of Kurarinone against corticosterone‐induced cytotoxicity on rat hippocampal neurons by targeting BACE1 to activate P13K–AKT signaling – A potential treatment in insomnia disorder

  2023cites this paper
• Experimental approaches for altering the expression of Abeta‐degrading enzymes

  2023cites this paper
• Astrocyte‐derived lactoferrin reduces β‐amyloid burden by promoting the interaction between p38 kinase and PP2A phosphatase in male APP/PS1 transgenic mice

  2023cites this paper
• Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer's disease.

  2022cites this paper
• Roburic Acid Targets TNF to Inhibit the NF-κB Signaling Pathway and Suppress Human Colorectal Cancer Cell Growth

  2022cites this paper
• Hypoxia Inducible Factor-1α binds and activates γ-secretase for Aβ production under hypoxia and cerebral hypoperfusion

  2022cites this paper
• Astrocyte-derived lactoferrin reduces Aβ burden by promoting the interaction of p38 and PP2A in APP/PS1 transgenic mice

  2022cites this paper
• Genome-wide DNA methylation profiling in nonagenarians suggests an effect of PM20D1 in late onset Alzheimer’s disease

  2021cites this paper
• Roburic acid attenuates osteoclastogenesis and bone resorption by targeting RANKL‐induced intracellular signaling pathways

  2021cites this paper
• Alzheimer's Disease and β-Secretase Inhibition: An Update With a Focus on Computer-Aided Inhibitor Design.

  2021cites this paper
• Roles of hepatic atypical protein kinase C hyperactivity and hyperinsulinemia in insulin‐resistant forms of obesity and type 2 diabetes mellitus

  2021cites this paper
• Examination of BDNF Treatment on BACE1 Activity and Acute Exercise on Brain BDNF Signaling

  2021cites this paper
• Plasma β‐secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD

  2021cites this paper
• The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2α in Neurodegeneration.

  2020cites this paper
• β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification

  2020cites this paper
• Atypical Protein Kinase C Hyperactivity in Insulin-Resistant and Insulin-Sensitive Forms of Alzheimer’s Disease: A Potential Therapeutic Target

  2020cites this paper
• Alteration in synaptic nanoscale organization dictates amyloidogenic processing in Alzheimer's disease

  2020cites this paper
• Plasma miRNAs as Biomarkers for Amnestic Mild Cognitive Impairment and Modulation on BACE1

  2020cites this paper
• Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease

  2020cites this paper
• Pharmacological activities of roburic acid: A review of literature

  2017cites this paper